TIDMRENX
Renalytix AI PLC
07 June 2021
Renalytix AI plc
("Renalytix" or the "Company")
Leadership additions announced to support expanding US
Government and Healthcare Provider KidneyIntelX Deployment
Enabling expertise in sales, population health and value-driven
care models
NEW YORK and SALT LAKE CITY, June 7, 2021 - Renalytix AI plc
(LSE: RENX) (NASDAQ: RNLX) announces a series of key hires to drive
its commercialization strategy in the United States market in light
of the recently announced Federal Government General Service
Administration payment contract and additional large healthcare
system partnerships. The combined background and experience of the
new leadership team is expected to drive adoption of the
KidneyIntelX testing and care model implementation in early-stage
diabetic kidney disease populations. Renalytix expects to continue
expanding its sales, marketing, and implementation teams with
expected KidneyIntelX roll-out beginning in the VA Medical Health
System in the 2(nd) half of 2021, and as the Company positions for
a broader national expansion beginning in fiscal 2022 in line with
expectations for a national Medicare insurance coverage
determination later this year.
Renalytix welcomes:
Missy Martin-Kemp will join Renalytix in June as Vice President
of Sales, Eastern U.S. Missy will recruit and lead a team of sales
representatives focused on supporting primary care physician (PCP)
and specialist practices utilizing KidneyIntelX testing as part of
health system, government, and payor collaborations. She will also
develop the recruiting, training, and management systems for
deploying a broader sales team in 2022. Missy brings over 15 years
of sales and sales leadership experience to Renalytix, with 10 of
those years focused on primary care. Most recently, she served as
the Chief Commercial Officer at Fibronostics. Prior to
Fibronostics, Missy held multiple sales and business development
leadership roles at CardioDx, a pioneer in Cardiovascular genomics.
At CardioDx she led efforts to deploy their laboratory tests in
private health systems and VA Centers and regional networks
(VISNs). She was responsible for successfully driving adoption and
revenue growth in primary care practices, including VA Community
Care Centers.
Christine Loftsgaarden has joined Renalytix as Vice President of
Commercial Partnerships. Christine will be focused on expanding
health system, federal government, and payor collaborations to
implement integrated care solutions based on KidneyIntelX risk
assessment in early-stage Diabetic Kidney Disease (DKD). Her
experience in successful population health-driven implementations
and value-based care models will be important to the continued
expansion of Renalytix's solutions in regional health systems and
VA centers. Her previous leadership experience includes a focus on
clinical delivery and practice optimization at Evolent Health where
she improved care delivery through the evaluation, prioritization
and development of strategic and innovative value-based care
solutions that enable rapid scaling across their market and
business model. Christine also worked at DaVita Healthcare Partners
where she led high priority clinical innovation projects from
concept to operationalization. She also led development and
implementation of a comprehensive diabetes management program for
DaVita patients.
Stacey Molinari has joined the commercial team as Director of
Commercial Partnerships focused on the northeast region. In this
role, she will work to expand the Mount Sinai KidneyIntelX program
to other regional and government owned health systems. Most
recently, Stacey was on the Market Access Account team covering the
Great Lakes Region which included New York, Michigan and Indiana at
Vifor Pharma, Inc (previously Relypsa). Prior to that, she worked
at Abbott Laboratories in roles of increasing responsibility.
Stacey has spent the majority of her career working with the
chronic kidney disease (CKD) population.
Jon Wisson has joined the Renalytix Managed Care Team as Senior
Manager, Government Access. Jon will lead contracting efforts with
Veterans Affairs (VA) centers and regional networks (VISNs),
military bases and Indian Health Services facilities. He brings
over 20 years of experience and success in direct government sales,
management and contracting with Cardinal Health, Pharmacia
Diagnostics, Terumo Medical, Cooper Genomics and Samsung
Neurologica. Jon's specialized government sales experience will be
a critical enabler for our success in contracting with the VA on
both a center and regional (VISN) basis in 2021 and 2022.
Andria Parks-Herrera has joined Renalytix as Vice President of
Marketing. Andria will direct Renalytix's communication efforts
across provider, payer and patient stakeholder groups and advance
key private and government partnerships focused on education, care
delivery and patient engagement to support adoption of
KidneyIntelX. Previously Andria led marketing for the Renal
Division of OPKO Health, Inc. She also brings knowledge and
experience with commercialization in Latin America, important as
Renalytix continues to build partnerships that form the foundation
for future international expansion.
"The Renalytix technology and market opportunity are attracting
a very high caliber of commercial talent," said Tom McLain,
Renalytix President. "This group brings first-hand professional
success launching and commercializing innovative solutions in both
private and government driven healthcare delivery models. Their
contributions will accelerate our expansion into new health systems
which in turn will drive adoption and revenue growth in 2022 and
2023."
For further information, please contact:
Renalytix AI plc www.renalytixai.com
James McCullough, CEO Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker) Tel: 020 7710 7600
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker) Tel: 020 7597 4000
Gary Clarence / Daniel Adams
Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391 303
About Kidney Disease
Kidney disease is now recognized as a public health epidemic
affecting over 850 million people globally. The Centers for Disease
Control and Prevention (CDC) estimates that 15% of US adults, or 37
million people, currently have chronic kidney disease (CKD).
Further, the CDC reports that 9 out of 10 adults with CKD do not
know they have it and 1 out of 2 people with very low kidney
function who are not on dialysis do not know they have CKD*. Kidney
disease is referred to as a "silent killer" because it often has no
symptoms and can go undetected until a very advanced stage. Each
year, kidney disease kills more people than breast and prostate
cancer. Every day, 13 patients in the United States die while
waiting for a kidney transplant.
*
https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of
artificial intelligence-enabled clinical in vitro diagnostic
solutions for kidney disease, one of the most common and costly
chronic medical conditions globally. The Company's lead product is
KidneyIntelX.com (visit www.kidneyintelx.com ) which is being
designed to help make significant improvements in kidney health
through early risk prognosis and optimal clinical care to reduce
the incidence of advanced kidney disease and kidney failure. For
more information, visit www.renalytix.com .
Forward-Looking Statements:
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, as amended. Examples of these forward-looking statements
include statements concerning: the potential for KidneyIntelX to
receive regulatory approval from the FDA, the commercial prospects
of KidneyIntelX, if approved, including whether KidneyIntelX will
be successfully distributed and marketed, our expectations
regarding reimbursement decisions, our plans for expansion of our
business and the ability of KidneyIntelX to curtail costs of
chronic and end-stage kidney disease, optimize care delivery and
improve patient outcomes. Words such as "anticipates," "believes,"
"estimates," "expects," "intends," "plans," "seeks," and similar
expressions are intended to identify forward-looking statements. We
may not actually achieve the plans and objectives disclosed in the
forward-looking statements, and you should not place undue reliance
on our forward-looking statements. Any forward-looking statements
are based on management's current views and assumptions and involve
risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or
implied in such statements. These risks and uncertainties include,
among others: that KidneyIntelX is based on novel artificial
intelligence technologies that are rapidly evolving and potential
acceptance, utility and clinical practice remains uncertain; we
have only recently commercially launched KidneyIntelX; and risks
relating to the impact on our business of the COVID-19 pandemic or
similar public health crises. These and other risks are described
more fully in our filings with the Securities and Exchange
Commission (SEC), including the "Risk Factors" section of our
annual report on Form 20-F filed with the SEC on October 28, 2020,
and other filings we make with the SEC from time to time. All
information in this press release is as of the date of the release,
and we undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events, or otherwise, except as required by law.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGUGDLLSGDGBL
(END) Dow Jones Newswires
June 07, 2021 02:00 ET (06:00 GMT)
Renalytix (LSE:RENX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From Apr 2023 to Apr 2024